おすすめの製品
由来生物
rabbit
品質水準
抗体製品の状態
affinity isolated antibody
抗体製品タイプ
primary antibodies
クローン
polyclonal
化学種の反応性
human
メーカー/製品名
Chemicon®
テクニック
ELISA: suitable
immunohistochemistry: suitable
適合性
not suitable for Western blot
not suitable for immunohistochemistry (Paraffin)
輸送温度
dry ice
ターゲットの翻訳後修飾
unmodified
遺伝子情報
human ... COL4A1(1282)
特異性
Antibody reacts with native and heat denatured human type IV collagen. Less than 10% cross reactivity with collagen types I, III, and V, and less than 1% with human collagen II. Antiserum was passed over immobilized human blood plasma proteins, and human collagen types I, III, and V. Human plasma proteins do not interfere with binding to collagen.
免疫原
Purified human placental collagen type IV
アプリケーション
Research Category
細胞骨格
細胞骨格
Research Sub Category
ECMタンパク質
ECMタンパク質
Anti-Collagen Type IV Antibody detects level of Collagen Type IV & has been published & validated for use in ELISA, IH.
ELISA on human collagen type IV: 1:3,000
Indirect immunofluorescent visualization of collagen type IV on cryostat sections of human tissue: 1:20-1:40, fresh frozen or acetone fixed specimens only.
Dot and slot blots: 1:300.
Not recommended for use in Western blot, or for use on paraffin-embedded tissue sections.
Optimal working dilutions must be determined by the end user.
Indirect immunofluorescent visualization of collagen type IV on cryostat sections of human tissue: 1:20-1:40, fresh frozen or acetone fixed specimens only.
Dot and slot blots: 1:300.
Not recommended for use in Western blot, or for use on paraffin-embedded tissue sections.
Optimal working dilutions must be determined by the end user.
物理的形状
Affinity purified antibody from cross-absorbed antiserum. Liquid in PBS containing mannitol, dextran and no preservatives.
Format: Purified
保管および安定性
Maintain at -20°C in undiluted aliquots for up to 12 months from date of receipt. Avoid repeated freeze / thaw cycles.
その他情報
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
法的情報
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our 製品選択ツール.
保管分類コード
12 - Non Combustible Liquids
WGK
WGK 2
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
AB748:
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Neuromuscular disorders : NMD, 28(8), 675-679 (2018-06-24)
Mutations in MYH2 that encodes myosin heavy chain IIa cause both dominant and recessively inherited myopathies. Patients with dominantly inherited MYH2 missense mutations present with ophthalmoplegia and progressive proximal limb weakness. Muscle biopsy reveals rimmed vacuoles and inclusions, prompting this
Frontiers in molecular biosciences, 9, 904526-904526 (2022-06-14)
Breast cancer is the most common cause of cancer death among women worldwide. Localized breast cancer can be cured by surgery and adjuvant therapy, but mortality remains high for tumors that metastasize early. Type IV collagen is a basement membrane
Clinical & experimental metastasis, 38(2), 175-185 (2021-03-04)
No reliable, non-invasive biomarker of metastatic breast cancer (mBC) exists: circulating CA15-3 (cCA15-3) is the marker mostly used to monitor mBC. Circulating collagen IV (cCOLIV) has been evaluated in other metastatic cancers and has been found to be a promising
Advanced healthcare materials, 6(11) (2017-03-25)
Pathological modification of the subendothelial extracellular matrix (ECM) has closely been associated with endothelial activation and subsequent cardiovascular disease progression. To understand regulatory mechanisms of these matrix modifications, the majority of previous efforts have focused on the modulation of either
Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo.
The Journal of Clinical Investigation null
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)